Melanoma Research Alliance - Advancing Drug Discovery to Identify New Therapies | Research Funding

The goal of this RFA is to provide initial support to identify new therapeutic modalities including small molecules, antibodies and cell therapies against validated melanoma targets; with an emphasis on targets that are applicable to rare melanoma subtypes. Support from this RFA will be geared towards early stages of the drug discovery continuum that could result in an optimized lead compound or biologic showing activity in appropriate melanoma preclinical models.

Duration:      1-2 years

Funding:       Up to $250,000 depending on the scope of the research project with potential for follow-on funding.

Eligibility: Researchers and clinicians within or outside the U.S. working in academic medical centers and universities or other non-profit research institutions are eligible to apply. Principal Investigators must hold a full-time faculty appointment at the level of Assistant Professor (or equivalent) or above.

How to Apply: Applications should be submitted the online portal ProposalCentral. Please note that an electronic ‘institutional signature' will be required to submit the proposal, please reach out to the Research Office in advance of submission.

Application Deadline: 28 March 2024

Further information

• More information about the program is available here.
• The online application can be found here.
• For electronic ‘institutional signature', please contact the Research Office
• For any other questions, please contact the Research Office.